NU-6300
CAS No. 2070015-09-5
NU-6300 ( NU 6300;NU6300 )
Catalog No. M13220 CAS No. 2070015-09-5
NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 312 | Get Quote |
|
50MG | 1341 | Get Quote |
|
100MG | 1791 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNU-6300
-
NoteResearch use only, not for human use.
-
Brief DescriptionNU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.
-
DescriptionNU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM; shows modest effect (GI50=8 uM) against human MCF-7 breast carcinoma cells; inhibits Rb phosphorylation in Rb-positive SKUT-1B cells.
-
SynonymsNU 6300;NU6300
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number2070015-09-5
-
Formula Weight413.49
-
Molecular FormulaC20H23N5O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=S(C1=CC=C(NC2=NC(OCC3CCCCC3)=C4N=CNC4=N2)C=C1)(C=C)=O
-
Chemical Name6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anscombe E, et al. Chem Biol. 2015 Sep 17;22(9):1159-64.
molnova catalog
related products
-
THZ1 2HCl
THZ1 2HCl is a selective, covalent, and allosteric inhibitor of CDK7 with an IC50 of 3.2 nM. THZ1 2HCl has antiproliferative effects on a variety of cancer cell lines.
-
CDK4-IN-1
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
-
M2I-1
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.